In Latvia, Roche is represented by a Pharmaceutical division since 1920. In 1940 Roche property was nationalized and company operations were stopped. In 1993 Roche returns in Latvia and in 1997 opens its representative office. Roche has a strong leading position on the market despite of tough competition from other companies. Roche focuses on areas of significant unmet medical needs and the fields where the company has the expertise to make a difference. Roche focuses on areas of significant unmet medical needs and the fields where the company has the expertise to make a difference. Consequently, the patients are now able to receive more and more innovative treatment options. Similarly to global Roche, Roche Latvia is the leading vendor of oncological drugs and leading conductor of oncological clinical trials. In the Latvia, Roche focuses on marketing and sales for the main therapeutic areas: Oncology, Virology, Infections, Central Nervous System Disorders and Metabolic Disorder. The long term goal is to provide personalized treatment solutions to Latvia’s healthcare system.
Contact:
Address: G. Astras 8b, 1082 Riga, Latvija
Tel. +371 6 703 98 31
Website: http://www.roche.lv/
Rauls Velins, Roche’s general manager for Latvia, introduces the company’s longstanding commitment to the Latvian market, Roche’s role in helping facilitate Latvia’s new National Cancer Plan, and the potential for…
Latvia has seen some major breakthroughs in recent years: more innovative medicines are available to patients than ever before; the market for commercial, OTC and reimbursable medicinal products has achieved…
Dr Valters Bolevics, director general of the Association of International Research-based Pharmaceuticals Manufacturers of Latvia (SIFFA), outlines the progress made on market access for innovative pharmaceuticals in Latvia in recent…
Dr Valters Bolevics, CEO of the Association of International Research-based Pharmaceutical Manufacturers (SIFFA) in Latvia, gives an overview of recent market changes affecting the Latvian pharmaceutical market, regulatory upgrades, and…
Vasily and Svetlana Bankovsky, founders of Biosan, talk about the company’s philosophy to develop modern, exciting personal products for sample preparation in the field of genomics, proteomics and cellomics and…
Anda Čakša, Latvia’s minister of health since 2016, discusses her current priorities, regulatory reform, areas of strengths and weaknesses in the nation’s healthcare infrastructure, e-health, and combating the threat of…
Inese Bolmane, business development manager at Latvian stem cell bank Cilmes Šūnu Banka, explains the basic rationale behind stem cell banking and what differentiates Cilmes Šūnu Banka from the competition.…
Janis Biezbardis, chairman and owner of Latvian pharmaceutical wholesaler Farmeko, discusses the evolution of the company’s product portfolio, the receptiveness of the Latvian state to homegrown companies, and Farmeko’s international…
Andrejs Pantelejevs, head of bureau of the Ministry of Health of Latvia, discusses the importance of channeling the recent EUR 200 million healthcare financing to raising the wages of practitioners,…
Juris Hmelnickis PhD, Chairman of the Board of JSC Kalceks, explains the story and the evolution of the company in Latvia, its key products in the CNS therapeutic area and…
Rauls Velins, Roche’s general manager for Latvia, introduces the company’s longstanding commitment to the Latvian market, Roche’s role in helping facilitate Latvia’s new National Cancer Plan, and the potential for…
Boriss Birmans, country manager of Santen Latvia, discusses the company’s focus on patient-centricity in the country, its ambition to bring in more preservative-free drugs for glaucoma patients and how its…
Janis Meiksans, general manager at TEVA Baltics, explains how the base of the company’s success is what they call ‘generic evangelism’ and how from being a marketing and distribution organization…
See our Cookie Privacy Policy Here
